Concepedia

Vladimir Vladimirov

VV

Statistics

Publications

26

Citations

4.5K

H-Index

20

Active since

2007

Affiliations

Pyatigorsk Oncology Center(Current)

Vall d'Hebron Hospital Universitari

Merck & Co., Inc., Rahway, NJ, USA (United States)

Vall d'Hebron Institute of Oncology

Hospital Universitario 12 De Octubre

Vladimir Vladimirov is an author at Pyatigorsk Oncology Center specializing in medicine, oncology, and cancer pharmacology.

Publications per year

2007–2024

26

Publications

26

Eribulin monotherapy versus treatment of physician's choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised study

Javier Cortés, Joyce O’Shaughnessy, David Loesch et al. · The Lancet · 2011 · 1.1K citations

, , +9

Pembrolizumab alone or combined with chemotherapy versus chemotherapy as first-line therapy for advanced urothelial carcinoma (KEYNOTE-361): a randomised, open-label, phase 3 trial

Thomas Powles, Tibor Csőszi, Mustafa Özgüroğlu et al. · The Lancet Oncology · 2021 · 648 citations · Full text

, , +11

A Randomized, Placebo-Controlled Trial of Pembrolizumab Plus Chemotherapy in Patients With Metastatic Squamous NSCLC: Protocol-Specified Final Analysis of KEYNOTE-407

Luis Paz‐Ares, David Vicente, Ali Tafreshi et al. · Journal of Thoracic Oncology · 2020 · 645 citations · Full text

, , +14

Lenvatinib plus pembrolizumab versus lenvatinib plus placebo for advanced hepatocellular carcinoma (LEAP-002): a randomised, double-blind, phase 3 trial

Josep M. Llovet, Masatoshi Kudo, Philippe Merle et al. · The Lancet Oncology · 2023 · 421 citations · Full text

, , +12

Phase III Trial of Ipilimumab Combined With Paclitaxel and Carboplatin in Advanced Squamous Non–Small-Cell Lung Cancer

Ramaswamy Govindan, Aleksandra Szczęsna, Myung‐Ju Ahn et al. · Journal of Clinical Oncology · 2017 · 380 citations · Full text

, , +14

1–5 of 26